Evidences support that dengue virus can impart broad‐spectrum immunity against betacoronaviruses in dengue endemic regions
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.29771 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Abinash Mallick und 3 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases and Immunology Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India. Hauptthemen laut MEDLINE: Dengue Virus, Dengue, Cross Reactions, Antibodies, Viral. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Council of Scientific and Industrial Research, India.
Abstract (Originalsprache)
COVID‐19 tended to be less aggressive in dengue endemic regions. Conversely, dengue cases plummeted in dengue endemic zones during the active years of the pandemic (2020–2021). We and others have demonstrated serological cross‐reactivity between these two viruses of different families. We further demonstrated that COVID‐19 serum samples that were cross‐reactive in dengue virus (DV) serological tests, “cross‐neutralized” all DV serotypes in Huh7 cells. Here we showed by co‐immunoprecipitation (Co‐IP) and atomic force microscopy (AFM) imaging that severe acute respiratory syndrome (SARS)‐coronavirus (CoV)‐2 (SARS‐CoV‐2) spike (S) protein subunit S1 and S2 monoclonal antibodies can indeed, bind to DV particles. Likewise, DV envelope antibodies (DV E Abs) showed high docking frequency with other human pathogenic beta‐CoVs and murine hepatitis virus‐1 (MHV‐1). SARS‐CoV‐2 Ab didn't show docking or Co‐IP with MHV‐1 supporting poor cross‐protection among CoVs. DV E Abs showed binding to MHV‐1 (AFM, Co‐IP, and immunofluorescence) and prepandemic dengue patients' serum samples even “cross‐neutralized” MHV‐1 plaques in cell culture. Furthermore, dengue serum samples showed marked inhibition potential in a surrogate virus‐based competitive enzyme‐linked immunosorbent assay, used for determining neutralizing Abs against SARS‐CoV‐2 S protein receptor‐binding domain in COVID‐19 serum samples. We therefore, provide multiple evidence as to why CoVs are epidemiologically less prevalent in highly dengue endemic regions globally.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases and Immunology Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India.
- CHINTA, TCG-Centres for Research and Education in Science and Technology, Kolkata, India.
- Department of Dermatology, Calcutta National Medical College and Hospital, Kolkata, India.
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
ORCID-Profile: Subhajit Biswas
Förderung
- Council of Scientific and Industrial Research, India
Zitieren
APA
Mallick, A., Sukla, S., De, A., & Biswas, S. (2024). Evidences support that dengue virus can impart broad‐spectrum immunity against betacoronaviruses in dengue endemic regions. Journal of Medical Virology. https://doi.org/10.1002/jmv.29771
Vancouver
Mallick A, Sukla S, De A, Biswas S. Evidences support that dengue virus can impart broad‐spectrum immunity against betacoronaviruses in dengue endemic regions. Journal of Medical Virology. 2024. doi:10.1002/jmv.29771
BibTeX
@article{Mallick2024,
author = {Mallick, Abinash and Sukla, Soumi and De, Abhishek and Biswas, Subhajit},
title = {Evidences support that dengue virus can impart broad‐spectrum immunity against betacoronaviruses in dengue endemic regions},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.29771}
}
EUVIMED